Focus on citalopram: A selective reuptake inhibitor for the treatment of depression

Formulary

Volumn 33, Issue 8, 1998, Pages 725-743

  Scates, Ann C ^a,b   Doraiswamy, P Murali ^b  

^a University of Connecticut   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE MALEATE; IMIPRAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG TOLERANCE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPOTHESIS; INSOMNIA; MAJOR CLINICAL STUDY; NAUSEA; NEUROTRANSMISSION; ORAL DRUG ADMINISTRATION; PANIC; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; STROKE; TREATMENT INDICATION;

EID: 0032439911     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Leonard BE. Serotonin receptors - where are they going? Int Clin Psychopharmacol 1994;9(Suppl 1):7-14.
2. Hytell J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(Suppl 1):19-26.
3. Montgomery SA, Djärv L. The antidepressant efficacy of citalopram. Int Clin Psychopharmacol 1996;11(SuppI 1):29-33.
4. Luo H, Richardson JS. A pharmacological comparison of citalopram, a bicyclic serotonin uptake inhibitor, with traditional tricyclic antidepressants. Int Clin Psychopharmacol 1993;8:3-12.
5. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-65.
6. Overo KF. Preliminary studies of the kinetics of citalopram in man. Eur J Clin Pharmacol 1978;14:69-73.
7. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1997;32 (Suppl 1):1-21.
8. Lane R, Baldwin D, Preskorn S. The SSRIs: Advantages, disadvantages and differences. J Psychopharmacol 1995;9(Suppl 2):163-78.
9. Foglia JP, Pollock BG, Kirshner MA, et al. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 1997;33:109-12.
10. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
11. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
12. Bech P, Cialdella P. Citalopram in depression - meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 1992;6(Suppl 5):45-54.
13. Montgomery SA, Rasmussen JGC, Lyby K, et al. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992;6(Suppl 5):65-70.
14. Feighner J, Overo K, Fieve R, et al. Fixed dose comparison of citalopram versus placebo in the treatment of outpatients with moderate to severe depression (poster No. 419). Presented at the 150th Annual Meeting, American Psychiatric Association;1997;San Diego.
15. Rosenburg C, Damsbo N, Fuglum E, et al. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol 1994;9(Suppl 1):41-8.